Abstract
Purpose: To evaluate some clinically important features of benzalkonium chloride (BAK) toxicity by comparing tafluprost with 0.001% BAK and travoprost preserved with SofZia applied to the ocular surface of the eyes with glaucoma. Methods: This was a prospective, randomized, observer unmasked, multicenter crossover trial. A total of 195 patients were randomized and 174 patients completed the study at 19 clinics between November 2011 and August 2012. Topical BAK-preserved tafluprost or SofZia-preserved travoprost was newly administered or continued. Superficial punctate keratopathy (SPK), tear break-up time (BUT), the conjunctival hyperemia score, and intraocular pressure (IOP) were compared at the baseline visit, 4, and 12 weeks after the start of therapy. The eye drops were switched to another eye drop after 12 weeks of observation. Results: The total SPK and conjunctival hyperemia scores were significantly lower in the tafluprost compared with those in the travoprost phase (both P=0.038). There were no significant differences in the SPK scores of the superior area (P=0.679), central area (P=0.089), inferior area (P=0.090), and tear BUT (P=0.271). The IOP-lowering effects were similar (P=0.155). Conclusions: SPK, hyperemia score, and tear BUT while using tafluprost with 0.001% BAK were not inferior compared with those caused by travoprost with SofZia.
| Original language | English |
|---|---|
| Pages (from-to) | 156-164 |
| Number of pages | 9 |
| Journal | Journal of Ocular Pharmacology and Therapeutics |
| Volume | 31 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Apr 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Ophthalmology
- Pharmacology
Cite this
Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and sofzia-preserved travoprost applied to the ocular surface. / The Ocular Surface Disease and Glaucoma Study Group; Ishihara, Rieko.
In: Journal of Ocular Pharmacology and Therapeutics, Vol. 31, No. 3, 01.04.2015, p. 156-164.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and sofzia-preserved travoprost applied to the ocular surface
AU - The Ocular Surface Disease and Glaucoma Study Group
AU - Kanamoto, Takashi
AU - Kiuchi, Yoshiaki
AU - Tanito, Masaki
AU - Mizoue, Shiro
AU - Naito, Tomoko
AU - Teranishi, Shinichiro
AU - Hirooka, Kazuyuki
AU - Rimayanti, Ulfah
AU - Mochizuki, Hideki
AU - Nakakura, Shunsuke
AU - Yasuhito, Ishida
AU - Shinichiro, Teranishi
AU - Sagara, Ken
AU - Shinkawa, Kuniisa
AU - Enoki, Miho
AU - Nakayama, Masako
AU - Yuta, Makiko
AU - Fukumura, Miho
AU - Murashige, Takashi
AU - Okuma, Shinichi
AU - Namiguchi, Koji
AU - Komatsu, Naoki
AU - Ishihara, Rieko
AU - Ishihara, Rieko
AU - Baba, Tetsuya
AU - Mizote, Masanobu
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Purpose: To evaluate some clinically important features of benzalkonium chloride (BAK) toxicity by comparing tafluprost with 0.001% BAK and travoprost preserved with SofZia applied to the ocular surface of the eyes with glaucoma. Methods: This was a prospective, randomized, observer unmasked, multicenter crossover trial. A total of 195 patients were randomized and 174 patients completed the study at 19 clinics between November 2011 and August 2012. Topical BAK-preserved tafluprost or SofZia-preserved travoprost was newly administered or continued. Superficial punctate keratopathy (SPK), tear break-up time (BUT), the conjunctival hyperemia score, and intraocular pressure (IOP) were compared at the baseline visit, 4, and 12 weeks after the start of therapy. The eye drops were switched to another eye drop after 12 weeks of observation. Results: The total SPK and conjunctival hyperemia scores were significantly lower in the tafluprost compared with those in the travoprost phase (both P=0.038). There were no significant differences in the SPK scores of the superior area (P=0.679), central area (P=0.089), inferior area (P=0.090), and tear BUT (P=0.271). The IOP-lowering effects were similar (P=0.155). Conclusions: SPK, hyperemia score, and tear BUT while using tafluprost with 0.001% BAK were not inferior compared with those caused by travoprost with SofZia.
AB - Purpose: To evaluate some clinically important features of benzalkonium chloride (BAK) toxicity by comparing tafluprost with 0.001% BAK and travoprost preserved with SofZia applied to the ocular surface of the eyes with glaucoma. Methods: This was a prospective, randomized, observer unmasked, multicenter crossover trial. A total of 195 patients were randomized and 174 patients completed the study at 19 clinics between November 2011 and August 2012. Topical BAK-preserved tafluprost or SofZia-preserved travoprost was newly administered or continued. Superficial punctate keratopathy (SPK), tear break-up time (BUT), the conjunctival hyperemia score, and intraocular pressure (IOP) were compared at the baseline visit, 4, and 12 weeks after the start of therapy. The eye drops were switched to another eye drop after 12 weeks of observation. Results: The total SPK and conjunctival hyperemia scores were significantly lower in the tafluprost compared with those in the travoprost phase (both P=0.038). There were no significant differences in the SPK scores of the superior area (P=0.679), central area (P=0.089), inferior area (P=0.090), and tear BUT (P=0.271). The IOP-lowering effects were similar (P=0.155). Conclusions: SPK, hyperemia score, and tear BUT while using tafluprost with 0.001% BAK were not inferior compared with those caused by travoprost with SofZia.
UR - http://www.scopus.com/inward/record.url?scp=84928102097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928102097&partnerID=8YFLogxK
U2 - 10.1089/jop.2014.0104
DO - 10.1089/jop.2014.0104
M3 - Article
C2 - 25710276
AN - SCOPUS:84928102097
VL - 31
SP - 156
EP - 164
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
SN - 1080-7683
IS - 3
ER -